Prosecution Insights
Last updated: November 04, 2026
Application No. 18/558,468

SPINOSYN PESTICIDAL COMPOSITIONS

Final Rejection §103§112
Filed
Nov 01, 2023
Priority
May 04, 2021 — provisional 63/183,942 +1 more
Examiner
BROWE, DAVID
Art Unit
1617
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Terramera Inc.
OA Round
2 (Final)
27%
Grant Probability
At Risk
3-4
OA Rounds
10m
Est. Remaining
55%
With Interview

Examiner Intelligence

Grants only 27% of cases
27%
Career Allowance Rate
198 granted / 740 resolved
-33.2% vs TC avg
Strong +28% interview lift
Without
With
+27.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
52 currently pending
Career history
803
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
46.6%
+6.6% vs TC avg
§102
6.9%
-33.1% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 740 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This action is in response to Applicant’s amendment filed August 19, 2026 in reply to the First Office Action on the Merits mailed May 19, 2026. Claims 2, 5, 7, 9-11, 14, 16-20, 22, 23, and 26-28 have been amended; and claims 3, 4, 6, 8, 12, 13, 15, 21, 24, 25, 29, 31-57, 60, and 61 have been canceled. Claims 5, 11, 16, 18, 22, 23, 26-28, 30, 58, and 59 have been withdrawn. Claims 1, 2, 7, 9, 10, 14, 17, 19, and 20 are under examination in the application. Withdrawal of Prior Claim Objections Claims 2, 7, 9, 10, 14, 17, 19, and 20 have been satisfactorily amended. Therefore, the objections to these claims presented in the First Office Action on the Merits mailed May 19, 2026 are hereby withdrawn. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 9, 14, 17, and 20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 9 and 14 stipulates that the composition further contains “an oil carrier” and that “the spinosyn active is less soluble in the oil carrier than in the salicylate solvent”, which renders the claim indefinite. In light of the specification, the “salicylate solvent” can be e.g. wintergreen oil, which is an oil. One of ordinary skill in the art thus cannot definitively ascertain what constitutes the salicylate solvent and what constitutes the “oil carrier”, i.e. what oils are thus necessarily excluded from being the “oil carrier”, such as wintergreen oil. This is on top of the indefiniteness issues already discussed with respect to claim 9. Claim 17, which depends from claim 1, provides in a wherein clause that “the salicylate solvent is provided in at least one of a botanical oil and a hydrophobic extract, in each case comprising an ester”, which renders the claim indefinite for the following reasons: 1. The expression “at least one of a botanical oil and a hydrophobic botanical extract” is awkward and indefinite as a botanical oil is a hydrophobic botanical extract. 2. Claim 1 appears to be limited to a salicylate compound as the solvent, and not merely an undefined solvent that happens to include a salicylate compound as but one constituent element thereof, in some undisclosed amount. Moreover, the present invention appears to make a distinction between the “salicylate solvent” and “an oil carrier”, but if the “salicylate solvent itself is an oil, this distinction is blurred and confusing. One of ordinary skill in the art thus cannot definitively ascertain the metes and bounds of the claimed subject matter. 3. One of ordinary skill in the art cannot definitively ascertain whether the salicylate solvent is necessarily an ester (i.e. the ester), or more generally, how the salicylate solvent is related to the required “ester”, if at all. ***Until further clarification, claim 17 is being interpreted at this time as the salicylate solvent is a salicylate compound, e.g. methyl salicylate, and not wintergreen oil. It is further noted that methyl salicylate, and not wintergreen oil, is the elected species of salicylate. Hence, if claim 17 intends for the solvent to be wintergreen oil, the claim will be withdrawn. Claim 20, which depends from claim 17, stipulates that “the salicylate solvent comprises a salicylate comprising an alkyl group”, which further compounds the indefiniteness as to whether the “ester” of claim 17 is necessarily the salicylate compound. Claim 20 is (also) indefinite for depending from an indefinite claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 7, 9, 10, 14, 17, 19, and 20 are rejected under 35 U.S.C. 103 as being unpatentable over Bessette et al. (U.S. Patent Application Pub. No. 2003/0194454), in view of Liu et al. (Chinese Patent Application Pub. No. CN 111567530 A). Applicant Claims Applicant’s elected subject matter is directed to a pesticide composition comprising Spinosad, methyl salicylate, and safflower oil; wherein the Spinosad is present in the amount of 0.01-30 wt%, and wherein the ratio of the Spinosad and the methyl salicylate is 1:1 to 1:10. Determination of the Scope and Content of the Prior Art (MPEP §2141.01) Bessette et al. disclose a pesticide composition comprising e.g. a pesticide active, wintergreen oil (i.e. methyl salicylate), and safflower oil; wherein the methyl salicylate is present in the amount of e.g. 22.5 wt% (abstract; paragraphs 0013, 0027, 0029, 0031, 0039, 0041, 0046, 0055, 0056, 0059, 0061, 0069, 0085). Liu et al. disclose a pesticide composition comprising e.g. 10 wt%, or 5-15 wt% Spinosad and an organic oil solvent; wherein Spinosad is a high-efficiency biological pesticide with very high insecticidal activity but no effect on most major beneficial insects on the target crop and also has a shorter environmental half-life.. Ascertainment of the Difference Between the Scope of the Prior Art and the Claims (MPEP §2141.02) Bessette et al. do not explicitly disclose that the pesticide active is Spinosad. This deficiency is cured by the teachings of Liu et al. Finding of Prima Facie Obviousness Rationale and Motivation (MPEP §2142-2143) It would have been prima facie obvious for one of ordinary skill in the art at the time the present application was filed to combine the respective teachings of Bessette et al. and Liu et al., outlined supra, to devise Applicant’s claimed composition. Bessette et al. disclose a pesticide composition comprising e.g. a pesticide active, methyl salicylate, and safflower oil; wherein the methyl salicylate is present in the amount of e.g. 22.5 wt%. Since Liu et al. disclose that e.g. 10 wt%, or 5-15 wt% Spinosad, when combined with an organic oil solvent, is a high-efficiency biological pesticide with very high insecticidal activity but no effect on most major beneficial insects on the target crop and also has a shorter environmental half-life; one of ordinary skill in the art would thus be motivated to employ Spinosad as the pesticidal active compound in the Bessette et al. composition, with the reasonable expectation that the resulting composition will successfully provide high pesticidal activity but no effect on most major beneficial insects on the target crop and with minimal environmental impact. In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Response to Arguments Applicant's arguments filed August 19, 2026 have been fully considered but they are not persuasive. i) Applicant contends that “Bessette is silent as to any activity or utility of wintergreen oil as a solvent”; that “Liu…is directed to the use of Spinosad…and is concerned with the stability of Spinosad when used in extreme environments”; that “Liu teaches that adding an organic solvent that is an aromatic hydrocarbon…and a fatty alcohol can improve low-temperature stability”; and thus that “there is no teaching or suggestion in Liu to select methyl salicylate as an organic solvent” and “the person skilled in the art following the teachings of Liu would be dissuaded from selecting methyl salicylate, which contains both an ester and an alcohol functional group”. The Examiner, however, would like to point out the following: 1. Applicant clearly has the cart before the horse. The prior art rejection under 35 USC 103 is over Bessette in view of Liu. Bessette is the primary reference. Therefore, it is Bessette that is being modified in view of Liu, not Liu that is being modified in view of Bessette. Hence, in stark contrast to Applicant’s assertion, Liu is not being modified in view of Bessette to employ methyl salicylate as the hydrocarbon solvent. Specifically, Liu is not being modified by throwing out the aromatic hydrocarbon solvent and replacing it with methyl salicylate. On the contrary, Bessette is being modified in view of Liu to employ Spinosad as the insecticidal agent. 2. Both Bessette and Liu are directed to insecticidal compositions, and there is simply so conflicts whatsoever in combining Bessette and Liu to arrive at an insecticidal composition. Neither the present claims nor Bessette necessarily exclude an aromatic hydrocarbon solvent. On the contrary, Bessette expressly discloses that an aromatic hydrocarbon carrier is suitable for their composition (see e.g. 0068). 3. Bessette discloses a pesticide composition comprising e.g. a pesticide active, wintergreen oil (i.e. methyl salicylate), and safflower oil; wherein the methyl salicylate is present in the amount of e.g. 22.5 wt%. In view of Liu, one of ordinary skill in the art would thus arrive at the presently claimed composition, i.e. a pesticide composition comprising Spinosad and methyl salicylate, and this is sufficient to preclude the patentability of the claimed composition. The cited prior art need not expressly teach that methyl salicylate is a solvent for Spinosad, and the reasons why the prior art may have combined the individual constituent elements to arrive at the composition need not be the very same reasons Applicant had for combining these same elements. For the foregoing reasons, the 35 USC 103 rejection is hereby maintained. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID BROWE whose telephone number is (571)270-1320. The examiner can normally be reached Monday - Friday, 9:30 AM to 6 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Liu can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID BROWE/Primary Examiner, Art Unit 1617
Read full office action

Prosecution Timeline

Nov 01, 2023
Application Filed
May 19, 2026
Non-Final Rejection mailed — §103, §112
Aug 19, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779022
BIOCOMPATIBLE NANOCOMPOSITE HYDROGEL IMMUNOTHERAPY VACCINES AND METHODS OF USE THEREOF
3y 8m to grant Granted Nov 03, 2026
Patent 12773472
Hemostatic Materials Based on Aldehyde-Functional Polysaccharides
3y 3m to grant Granted Oct 27, 2026
Patent 12758639
USE OF A BORON CLUSTER AS TRANSMEMBRANE CARRIER
3y 9m to grant Granted Oct 13, 2026
Patent 12751471
Pet Food Compositions
4y 3m to grant Granted Oct 06, 2026
Patent 12740566
ENHANCED HERBICIDAL COMPOSITIONS OF TRANSITION METAL CHELATES
3y 2m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
27%
Grant Probability
55%
With Interview (+27.8%)
3y 11m (~10m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 740 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month